ERBB2 and triple-negative breast carcinoma: In addition to the enhanced effect on retarding tumor growth in triple negative breast cancer models, we also observed an improved anti-cancer effect by combining ribociclib, D 4476, and trastuzumab in treating BT-474 HER2-positive breast tumor (Fig. 7k, Supplementary Fig. 7h).